MyMD Pharmaceuticals (MYMD) & Its Peers Head-To-Head Comparison

MyMD Pharmaceuticals (NASDAQ:MYMDGet Rating) is one of 40 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its peers? We will compare MyMD Pharmaceuticals to similar businesses based on the strength of its profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.


This table compares MyMD Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MyMD Pharmaceuticals N/A -77.76% -69.92%
MyMD Pharmaceuticals Competitors -2,615.40% -73.84% -34.36%

Valuation & Earnings

This table compares MyMD Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
MyMD Pharmaceuticals $1.58 million -$29.89 million -5.98
MyMD Pharmaceuticals Competitors $411.38 million $32.43 million -65.69

MyMD Pharmaceuticals’ peers have higher revenue and earnings than MyMD Pharmaceuticals. MyMD Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

12.4% of MyMD Pharmaceuticals shares are held by institutional investors. Comparatively, 49.2% of shares of all “Diagnostic substances” companies are held by institutional investors. 11.3% of MyMD Pharmaceuticals shares are held by insiders. Comparatively, 11.2% of shares of all “Diagnostic substances” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

MyMD Pharmaceuticals has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals’ peers have a beta of 1.40, meaning that their average share price is 40% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for MyMD Pharmaceuticals and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MyMD Pharmaceuticals 0 0 0 0 N/A
MyMD Pharmaceuticals Competitors 200 545 1145 18 2.51

As a group, “Diagnostic substances” companies have a potential upside of 77.25%. Given MyMD Pharmaceuticals’ peers higher possible upside, analysts clearly believe MyMD Pharmaceuticals has less favorable growth aspects than its peers.


MyMD Pharmaceuticals peers beat MyMD Pharmaceuticals on 7 of the 10 factors compared.

MyMD Pharmaceuticals Company Profile

(Get Rating)

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Receive News & Ratings for MyMD Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyMD Pharmaceuticals and related companies with's FREE daily email newsletter.